“Exosomes Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Exosomes Market.
The Exosomes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Exosomes Pipeline Report:
Companies across the globe are diligently working toward developing novel Exosomes treatment therapies with a considerable amount of success over the years.
Exosomes companies working in the treatment market are Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, Endosome Therapy StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Aegle Therapeutics, Regeneus, Direct Biologics, Capricor Therapeutics, and others, are developing therapies for the Exosomes treatment
Emerging Exosomes therapies in the different phases of clinical trials are- ExoCoVac, COYA 201, EV-101, StemXO, BRE AD01, ILB 202, Zofin, exoSTING, AGLE 102, Progenza, ExoFl, CAP-1002, and others are expected to have a significant impact on the Exosomes market in the coming years.
In June 2025, Rion Aesthetics, a globally recognized leader in regenerative aesthetics, announced that the U.S. Food and Drug Administration (FDA) has approved the initiation of a Phase 1 investigator-initiated clinical trial under an Investigational New Drug (IND) application. The trial will evaluate intradermal injections of its Purified Exosome Product™ (PEP™). This study is independently sponsored and conducted by the Clinical Testing Center of Beverly Hills, with Dr. John H. Joseph, a double board-certified facial plastic surgeon in California, serving as the lead investigator.
In January 2025, RION, a clinical-stage regenerative medicine company at the forefront of exosome-based therapeutics, has successfully completed patient enrollment in its Phase 2 clinical trial for Purified Exosome Product™ (PEP™), aimed at treating Diabetic Foot Ulcers (DFUs). This milestone marks a significant step forward in the company’s mission to create groundbreaking therapies for chronic wound care.
In January 2025, NurExone Biologic announced the acquisition of a master cell bank from a U.S. manufacturer. This acquisition is a key milestone in ensuring a stable and scalable supply chain for the production of exosome-based therapies, meeting clinical needs and laying the foundation for future patient treatments.
In July 2024, Aruna Bio announced that it has been granted a US patent for the composition of neural exosomes intended to deliver therapeutics directly to the brain.
Exosomes Overview
Exosomes are small membrane-bound vesicles that are released by cells into the extracellular space. These vesicles play a crucial role in intercellular communication by transporting various biomolecules, including proteins, lipids, and nucleic acids, between cells. Exosomes are a type of extracellular vesicle, and they are part of the body’s natural communication system.
Get a Free Sample PDF Report to know more about Exosomes Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/exosomes-pipeline-insight
Emerging Exosomes Drugs Under Different Phases of Clinical Development Include:
ExoCoVac: Innovex Therapeutics
COYA 201: Coya Therapeutics
EV-101: EV Therapeutics
StemXO: Endosome Therapy StemXO Therapeutics
BRE AD01: Brexogen
ILB 202: ILIAS Biologics
Zofin: Organicell Regenerative Medicine
exoSTING: Codiak BioSciences
AGLE 102: Aegle Therapeutics
Progenza: Regeneus
ExoFlo: Direct Biologics
CAP-1002: Capricor Therapeutics
Exosomes Route of Administration
Exosomes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Exosomes Molecule Type
Exosomes Products have been categorized under various Molecule types, such as
Oligonucleotide
Peptide
Small molecule
Exosomes Pipeline Therapeutics Assessment
Exosomes Assessment by Product Type
Exosomes By Stage and Product Type
Exosomes Assessment by Route of Administration
Exosomes By Stage and Route of Administration
Exosomes Assessment by Molecule Type
Exosomes by Stage and Molecule Type
DelveInsight’s Exosomes Report covers around 100+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Exosomes product details are provided in the report. Download the Exosomes pipeline report to learn more about the emerging Exosomes therapies
Some of the key companies in the Exosomes Therapeutics Market include:
Key companies developing therapies for Exosomes are – Qiagen, Thermo Fisher Scientific Inc., Illumina Inc., Takara Bio Inc., Malvern Instruments Ltd, Abcam PLC, Evox Therapeutics, Danaher Corporation (Beckman Coulter Inc.), Hologic Inc., Fujifilm Holdings Corporation, Lonza Group Ltd, JSR Corporation (MBL International), Miltenyi Biotec, Bio-Techne (Novus Biologicals), Capricor Therapeutics Inc., and others.
Exosomes Pipeline Analysis:
The Exosomes pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Exosomes with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Exosomes Treatment.
Exosomes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Exosomes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Exosomes market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Exosomes drugs and therapies
Exosomes Pipeline Market Drivers
Exosomes as an emerging messenger in diagnostics, a rise in exosome-based drug development, exosomes as a promising tool in the field of nanomedicine are some of the important factors that are fueling the Exosomes Market.
Exosomes Pipeline Market Barriers
However, lack of standardized techniques for the isolation and purification of exosomes, lack of scalable manufacturing processes and other factors are creating obstacles in the Exosomes Market growth.
Scope of Exosomes Pipeline Drug Insight
Coverage: Global
Key Exosomes Companies: Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, Endosome Therapy StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Aegle Therapeutics, Regeneus, Direct Biologics, Capricor Therapeutics, and others
Key Exosomes Therapies: ExoCoVac, COYA 201, EV-101, StemXO, BRE AD01, ILB 202, Zofin, exoSTING, AGLE 102, Progenza, ExoFl, CAP-1002, and others
Exosomes Therapeutic Assessment: Exosomes current marketed and Exosomes emerging therapies
Exosomes Market Dynamics: Exosomes market drivers and Exosomes market barriers
Request for Sample PDF Report for Exosomes Pipeline Assessment and clinical trials
Table of Contents
1. Exosomes Report Introduction
2. Exosomes Executive Summary
3. Exosomes Overview
4. Exosomes- Analytical Perspective In-depth Commercial Assessment
5. Exosomes Pipeline Therapeutics
6. Exosomes Late Stage Products (Phase II/III)
7. Exosomes Mid Stage Products (Phase II)
8. Exosomes Early Stage Products (Phase I)
9. Exosomes Preclinical Stage Products
10. Exosomes Therapeutics Assessment
11. Exosomes Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Exosomes Key Companies
14. Exosomes Key Products
15. Exosomes Unmet Needs
16 . Exosomes Market Drivers and Barriers
17. Exosomes Future Perspectives and Conclusion
18. Exosomes Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
